Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02120638
Other study ID # KY2013-260
Secondary ID 2013ZX10003008-0
Status Recruiting
Phase Phase 3
First received April 21, 2014
Last updated April 21, 2014
Start date April 2014
Est. completion date April 2016

Study information

Verified date April 2014
Source Huashan Hospital
Contact Wenhong Zhang, PhD,MD
Phone +86 21 52889999
Email zhangwenhong@fudan.edu.cn
Is FDA regulated No
Health authority China: Ministry of Science and Technology
Study type Interventional

Clinical Trial Summary

Multidrug resistant tuberculosis (MDR-TB) is difficult to treat and raises a great challenge to TB control program. That pyrazinamide can shorten the course of treatment and facilitate bacilli clearance has been proved recently. In 2011, WHO recommended to use pyrazinamide throughout the course of treatment for MDR-TB. However, pyrazinamide susceptibility testing has not been widely used in clinic. And the conventional testing is time-consuming and unreliable. In contrast, the detection of pncA and rpsA mutations with molecular methods can provide rapid results of pyrazinamide susceptibility. The purpose of this study is to evaluate the efficacy of the introduce the molecular testing of pyrazinamide susceptibility in optimizing the MDR-TB treatment regimen.


Description:

This is a phase 3, open labeled, prospective cohort study to evaluate the molecular testing of pyrazinamide susceptibility in optimizing the MDR-TB treatment regimen. Approximately 100 participants will be given the molecular detection of pncA and rpsA mutations and divide into to the pyrazinamide sensitive comparator group and the pyrazinamide resistant group based on the susceptibility results. For the pyrazinamide sensitive group, the regimen contains six months of chemotherapy with pyrazinamide, amikacin, levofloxacin, plus prothionamide, followed by six months of pyrazinamide, levofloxacin, clarithromycin, plus prothionamide. For the pyrazinamide resistant group, the regimen contains six months of chemotherapy with isoniazid, amikacin, levofloxacin, plus prothionamide, followed by eighteen months of isoniazid, levofloxacin, clarithromycin, plus prothionamide.

The participants will be followed up to 24 months after the start of the treatment. The primary outcome is the sputum culture conversion and the adverse events. Safety evaluations that will be performed are the routine lab tests, blood glucose, hearing , vital signs, ECG, reporting of adverse events, physical examinations and X-rays.


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date April 2016
Est. primary completion date April 2016
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria:

- Patients who are diagnosed with active tuberculosis

- Patients who are smear positive and sputum culture positive for tuberculosis

- History of active tuberculosis less than 3 years

- With less than 2 times of previous antituberculous therapy

- The patients should be voluntarily entering the study and willing to sign up the consent form after full knowledge of the risks, schedule, drug features of this study.

- MDR-TB is defined as resistance to the following two drugs: Isoniazid and Rifampicin.

- Extensively drug-resistant(XDR-TB) is defined as resistance to any flouroquinolones and any one of the three second-line antituberculous injections (capreomycin, kanamycin, amikacin)

- The study enrolled MDR-TB subjects and excluded XDR-TB subjects. If MDR-TB subjects is also resistant to flouroquinolones or capreomycin( kanamycin, amikacin), the subjects is included in the study as pre-XDR TB patients.

Exclusion Criteria:

- Known allergy or intolerance to the drugs in this study

- Liver damage (Hepatic encephalopathy; ascites; prothrombin time prolonged 2 seconds compared with normal controls; blood bilirubin 3 times greater than the upper limit of the normal range)

- Platelets <150x109 / L, WBC < 3x109 / L.

- Abnormal ECG (Male patients with prolonged QT interval exceeding 430ms, Female patients with prolonged QT interval exceeding 450ms)

- Serum creatinine 1.5 times higher than upper limit

- Fasting blood-glucose higher than 8.0 mmol/L

- Patients who are on medication that effect the results of the drugs in this study

- Karnofsky score<50% (see appendix)

- Women who are pregnant or breastfeeding

- HIV positive

- Participating in other clinical trials in the past three months

- Patients with mental illness and severe neurosis

- Patients who have poor compliances

- Any special circumstances in which the research physicians believe that is not suitable for this study.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Pyrazinamide containing regimen
Pyrazinamide 33-50kg 1000-1750 mg daily, 51-70kg 1750-2000 daily, >70kg 2000-2500mg daily Amikacin 600mg daily Levofloxacin 33-70kg 750 mg daily, >70kg 1000 mg daily Clarithromycin 33-50kg 500 mg daily, >50kg 1000 mg daily Prothionamide 33-50kg 500 mg daily, 51-70kg 750 daily, >70kg 1000 mg daily All treatment is taken daily, for a duration of up to 12 months depending on treatment arm.
Regimen without Pyrazinamide
Isoniazid 600mg daily Amikacin 600mg daily Levofloxacin 33-70kg 750 mg daily, >70kg 1000 mg daily Clarithromycin 33-50kg 500 mg daily, >50kg 1000 mg daily Prothionamide 33-50kg 500 mg daily, 51-70kg 750 daily, >70kg 1000 mg daily All treatment is taken daily, for a duration of up to 18 months depending on treatment arm.

Locations

Country Name City State
China Chongqing Pulmonary Hospital Chongqing Chongqing
China Hangzhou Red Cross Hospital Hangzhou Zhejiang
China The Affiliated Hospital of Hangzhou Normal University Hangzhou Zhejiang
China The Affiliated Hospital of Luzhou Medical College Huzhou Zhejiang
China The Fifth People's Hospital of Suzhou Suzhou Jiangsu
China Wenling No.1 People's Hospital Taizhou Zhejiang
China Xinjiang Chest Hospital Urumqi Xinjiang
China Ruian People's Hospital Wenzhou Zhejiang
China The Fifth People's Hospital of Wuxi Wuxi Jiangsu
China The Sixth People's Hospital of Zhengzhou Zhengzhou Henan
China Zhuji People's Hospital of Zhejiang Province Zhuji Zhejiang

Sponsors (1)

Lead Sponsor Collaborator
Huashan Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary The Median Time to Sputum Culture Conversion 24 months No
Secondary The Percentage of treatment success Treatment success is defined as:
During the last 12 months of treatment,participants have at least 5 sputum cultures negative taken at least 30 days apart.
During the last 12 months of treatment,participants have only one sputum culture positive, followed by at least 3 consecutive sputum cultures negative taken at least 30 days apart, without symptoms progression.
Participants complete the treatment, but less than 5 culture results are available.
24 months No
See also
  Status Clinical Trial Phase
Recruiting NCT05017324 - Sequencing Mycobacteria and Algorithm-determined Resistant Tuberculosis Treatment Trial N/A
Active, not recruiting NCT02496572 - Effectiveness of a Simplified Short Regimen for Multidrug Resistant Tuberculosis in Uzbekistan Phase 3
Completed NCT03942354 - Patient-reported Experiences and Quality of Life Outcomes in the TB-PRACTECAL Clinical Trial
Completed NCT02454205 - An Open-label RCT to Evaluate a New Treatment Regimen for Patients With Multi-drug Resistant Tuberculosis Phase 2/Phase 3
Recruiting NCT05081401 - Innovating(IN) Shorter(S), All- Oral, Precised(P), Individualized(I) Treatment Regimen(RE) for Rifampicin Resistant Tuberculosis(INSPIRE-TB)
Completed NCT01856634 - Pharmacokinetic and Safety Trial to Determine the Appropriate Dose for Pediatric Patients With Multidrug Resistant Tuberculosis Phase 1
Active, not recruiting NCT03867136 - Refining MDR-TB Treatment (T) Regimens (R) for Ultra(U) Short(S) Therapy(T) Phase 4
Not yet recruiting NCT04484129 - MDR-TB Close Contacts Tracing in China (TCCT Study)
Completed NCT00727844 - Linezolid to Treat Extensively-Drug Resistant Tuberculosis Phase 2
Completed NCT01859923 - A 6-Month Safety, Efficacy, and Pharmacokinetic (PK) Trial of Delamanid in Pediatric Participants With Multidrug Resistant Tuberculosis (MDR-TB) Phase 2
Active, not recruiting NCT04421495 - Safety and Effectiveness of Delamanid-containing Regimen for MDR-TB Patients in China Phase 4
Active, not recruiting NCT04717908 - Refining MDR-TB Treatment (T) Regimens (R) for Ultra(U) Short(S) Therapy(T)-PLUS N/A
Not yet recruiting NCT03604848 - NGS-Guided(G) Regimens(R) of Anti-tuberculosis(A) Drugs for the Control(C) and Eradication(E) of MDR-TB N/A
Recruiting NCT05534750 - Evaluation of the Early Bactericidal Activity of Tedizolid and Linezolide Against Mycobacterium Tuberculosis (TEDITUB) Phase 2